Skip to main content

Site Search

Choose Location

International
Americas
Asia Pacific
Europe
Middle East & Africa

: Global | English
: Novartis Foundation | English

: Argentina Test | Español root
: US test | American
: Brazil | Português
: Canada | English
: Canada | Français
: Central America | Español
: Colombia | Español
: Mexico | Español
: United States | English

: Bangladesh | English
: Hong Kong S.A.R. | 繁體中文
: India | English
: Indonesia | English
: Japan | 日本語
: Korea | 한국어
: Mainland China | 中文
: Malaysia | English
: Pakistan | English
: Philippines | English
: Singapore | English
: Taiwan | 繁體中文
: Thailand | ภาษาไทย

: English Chagned Test | English Chagned Test
: UK2 | English
: Austria Tesst | Deutsch
: Belgium | Français
: Belgium | Nederlands
: Bulgaria | Български
: Czech Republic | Česky
: Czech Republic | English
: Denmark | Dansk
: Estonia | Eesti
: Finland | Suomalainen
: France | Français
: Germany | Deutsch
: Greece | Ελληνικά
: Hungary | Magyar
: Ireland | English
: Italy | Italiano
: Latvia | Latvian
: Lithuania | Lithuanian
: Netherlands | Nederlands
: Norway | Norsk
: Poland | Polski
: Portugal | Português
: Romania | Română
: Russia | Русский
: Serbia | Srpski
: Slovakia | Slovensky
: Slovenia | Slovenščina
: Slovenia | English
: Spain | Español
: Sweden | Svenska
: Switzerland | Deutsch
: Switzerland | Français
: Türkiye | Türkçe
: United Kingdom | English

: Australia ER Test Tesst | English
: Egypt | English
: Israel | עברית
: Saudi Arabia | العربية
: South Africa | English

Choose Location

International Americas Asia Pacific Europe Middle East & Africa

: Argentina Test | Español root
: English Chagned Test | English Chagned Test
: UK2 | English
: US test | American
: Australia ER Test Tesst | English
: Austria Tesst | Deutsch
: Bangladesh | English
: Belgium | Français
: Belgium | Nederlands
: Brazil | Português
: Bulgaria | Български
: Canada | English
: Canada | Français
: Central America | Español
: Colombia | Español
: Czech Republic | Česky
: Czech Republic | English
: Denmark | Dansk
: Egypt | English
: Estonia | Eesti
: Finland | Suomalainen
: France | Français
: Germany | Deutsch
: Greece | Ελληνικά
: Hong Kong S.A.R. | 繁體中文
: Hungary | Magyar
: India | English
: Indonesia | English
: Ireland | English
: Israel | עברית
: Italy | Italiano
: Japan | 日本語
: Korea | 한국어
: Latvia | Latvian
: Lithuania | Lithuanian
: Mainland China | 中文
: Malaysia | English
: Mexico | Español
: Netherlands | Nederlands
: Norway | Norsk
: Global | English
: Novartis Foundation | English
: Pakistan | English
: Philippines | English
: Poland | Polski
: Portugal | Português
: Romania | Română
: Russia | Русский
: Saudi Arabia | العربية
: Serbia | Srpski
: Singapore | English
: Slovakia | Slovensky
: Slovenia | Slovenščina
: Slovenia | English
: South Africa | English
: Spain | Español
: Sweden | Svenska
: Switzerland | Deutsch
: Switzerland | Français
: Taiwan | 繁體中文
: Thailand | ภาษาไทย
: Türkiye | Türkçe
: United Kingdom | English
: United States | English

About

Board of Directors

Giovanni Caforio

Simon Moroney

Ton Buechner

Patrice Bula

Elizabeth (Liz) Doherty

Ana de Pro Gonzalo

Bridgette Heller

Daniel Hochstrasser

Frans van Houten

Elizabeth McNally

John D. Young

Charlotte Pamer-Wieser

Executive Committee

Vasant (Vas) Narasimhan

Shreeram Aradhye

Victor Bulto

Aharon (Ronny) Gal

Karen L. Hale

Patrick Horber

Harry Kirsch

Rob Kowalski

Steffen Lang

Fiona Marshall

Lutz Hegemann

Kees Roks

Michelle Weese

Products

Therapeutic areas

Cardiovascular, renal and metabolic

Immunology

Neuroscience

Oncology

People and culture

Inclusion

Promoting inclusion

Building belonging

Parental leave

Novartis Gene Therapies

Manufacturing

Quality

Audit program

Novartis quality management system (QMS)

Product and patient safety training

Regulatory inspections

Product recalls

Third-party suppliers

Awards and recognition

About

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Patients and caregivers

Novartis commitment to patients and caregivers

Diseases

Patient organization funding

Patients perspectives stories

Patients and caregivers

Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

Healthcare professionals

Medical congresses and events

ASCO Annual Meeting

Products

Novartis pipeline

Managed access programs

Zolgensma® Global Managed Access Program (gMAP)

Novartis external funding

Healthcare professional resources by country

Investigator-initiated trials / studies

Novartis medical information

Submit medical enquiry

Healthcare professionals

Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

Research and development

Technology platforms

Research disease areas

Cardiovascular and metabolic disease research at Novartis

DAx: exploratory disease research at Novartis

Global Health disease area research at Novartis

Immunology disease research at Novartis

Neuroscience research at Novartis

Oncology research at Novartis

Novartis pipeline

Research collaborations

Collaborations

Research & development

Discover how Novartis turns breakthrough science into transformative, high-value treatments.

ESG

Access

Creating sustainable business models

Value-based pricing

Sub-Saharan Africa

Donations

Novartis access principles

Novartis oncology access

Patents and licensing

Environmental sustainability

Climate

Nature - Waste

Nature - Water

Ethics, risk and compliance

Ethical behavior

Compliance

Human rights

Learning and engagement

Integrated risk assurance

Global health

Pandemic preparedness

Avoidable blindness

Chagas disease

Leprosy

Malaria

Sickle cell disease (SCD)

Novartis Foundation

Inclusion

ESG index

Reporting and transparency hub

ESG rating performance

Targets

Patient organization funding

Payments to healthcare professionals

Public policy

A living wage

A safe workplace

Animal research

Environmental, social and governance

Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

Investors

Event calendar

Financial data

Novartis annual results

Novartis quarterly results

Novartis SEC filings

Product sales

Fixed-income securities

Expected currency impact

Share data and analysis

Share monitor

Dividend information

Share ownership

Share overview

Return on investment calculator

Shareholder information

General Meetings

American Depositary Receipts (ADR)

Share buyback

Frequently asked questions

Company overview

Corporate governance

Reporting and transparency hub

Reporting archive

ESG rating performance

Publications order form

ESG

Investors

Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

News

News archive

Media library

Stories

Subscribe

Events

News

Information for journalists including media releases, statements, stories, multimedia resources and more.

Careers

Career search

Our business functions

Careers in research and development

Careers in operations

Careers in commercial and sales

Careers in global functions

Why Novartis

Career hub

Temporary contracts

Early careers

Graduates

Students

US Biomedical Research internship programs

Community exploration and learning lab (CELL)

Careers

Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

Clinical trials

Partnering

Supplier portal

Report side effects

Contacts
Home

Working together, we can reimagine medicine to improve and extend people’s lives.

Header

Home
News
News Archive

News Archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

Date Range

News Type Filters

Language

Start Date

End Date

News Archive Navigation

All
Media Releases
Key Releases
Featured News
Statements
Pulse Updates
Stories

icon

News Archive Navigation Language

Language Preferences Language

English
German
French

Showing 1866 results

May 2025

Featured News May 29, 2025
Test feature
Featured News May 29, 2025
Featured News - ESG

intro
Featured News May 29, 2025
Test new
Featured News May 28, 2025
Featured News validation
Featured News May 26, 2025
Test push config updating

Featured Headline / Intro text
Featured News May 26, 2025
Tests Feature News
Featured News May 22, 2025
Featured News
Featured News May 22, 2025
Featured News child
Story May 22, 2025
Satellite site - Automatic push and manual pull - no image - root
Key Release May 22, 2025
Satellite site - Automatic push and manual pull - Story Root
Featured News May 22, 2025
Feature News English for German Translation and push

Featured Headline / Intro text
Column 1 content
Column 2 content
Featured News May 20, 2025
Feature with no image

test

Pagination

‹ Previous page
1
2
3
4
5
6
7
…
156
› Next page

Novartis

Working together

Patients and caregivers
Healthcare professionals
Researchers
Job seekers
Journalists
Investors

Topics

Eurovision
Access
ESG
SpeakUp

Explore

Pipeline
Products
Clinical trials
Partnering
Events

Therapeutic areas

Cardiovascular, renal and metabolic
Immunology
Neuroscience
Oncology

Footer Site Search

Footer Bottom

© 2025 Novartis AG

Terms of use
Privacy
Cookie settings
Contacts
Locations
Site map
Open source
Web accessibility

Novartis Site Directory

This site is intended for a global audience